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SUMMARY  8 
Considerable evidence suggests that mitochondrial dysfunction occurs early in Alzheimer’s 9 
disease, both in affected brain regions and in leukocytes, potentially precipitating 10 
neurodegeneration through increased oxidative stress. Epigenetic processes are emerging 11 
as a dynamic mechanism through which environmental signals may contribute to cellular 12 
changes, leading to neuropathology and disease. Until recently little attention was given 13 
to the mitochondrial epigenome itself, as preliminary studies indicated an absence of DNA 14 
modifications. However, recent research has demonstrated that epigenetic changes to the 15 
mitochondrial genome do occur, potentially playing an important role in several disorders 16 
characterized by mitochondrial dysfunction. This review explores the potential role of 17 
mitochondrial epigenetic dysfunction in Alzheimer’s disease etiology and discusses some 18 
technical issues pertinent to the study of these processes. 19 
 20 
 21 
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 23 
Alzheimer’s disease (AD) is a chronic, currently incurable, neurodegenerative disorder, 24 
accounting for more than 60% of dementia cases, with current estimates predicting more 25 
than 135 million dementia cases worldwide by 2050 [1]. The classic neuropathological 26 
hallmarks associated with AD include the formation of amyloid beta (Aβ) plaques and 27 
neurofibrillary tangles. These are suggested to play a role in the further development of 28 
other characteristics of the disease, such as disruption of calcium homeostasis, loss of 29 
connectivity, the generation of reactive oxidative species (ROS) and altered plasticity, 30 
ultimately leading to neurodegeneration [2-6]. Mitochondrial dysfunction is a consistent 31 
feature of AD pathology in both the brain and white blood cells [7-10] although the 32 
molecular mechanism(s) mediating this phenomena are yet to be fully elucidated. 33 
 34 
Mitochondrial dysfunction: a prominent feature of AD 35 
Being the site of ATP generation, mitochondria provide the cell with the energy required to 36 
properly function; as such they are often described as ‘the powerhouse of the cell’. 37 
Mitochondria are cylindrical organelles containing ~16.6kb of DNA (mtDNA) [11], which is 38 
separate to the nuclear genome and inherited in a maternal, non-Mendelian fashion. The 39 
mitochondrial genome consists of 37 genes, 13 of which encode for polypeptides required 40 
for the electron transport chain (ETC) (Figure 1), in addition to two ribosomal RNAs and 22 41 
transfer RNAs. The mitochondria play a vital role in a variety of key biological functions, 42 
including apoptosis via caspase dependent and independent mechanisms [12], the 43 
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regulation of calcium homeostasis [13, 14] and the production of ROS [15]. For these 44 
reasons, mitochondrial dysfunction has been implicated in the pathogenesis associated with 45 
AD [16, 17] and forms the basis of the mitochondrial cascade hypothesis [18]. Proposed by 46 
Swerdlow et al, this hypothesis states that an individual’s genetic code will determine their 47 
basal mitochondrial function and that, throughout ageing, this function will decline due to a 48 
combination of genetic and environmental factors, determining an individual’s time of 49 
disease onset [18].  50 
 51 
Mitochondrial-encoded ETC gene expression has been shown to be altered in both early and 52 
late stages of AD, with decreased expression of complex I and increased expression of 53 
complexes III and IV [7]. Increased expression of mitochondrial-encoded ETC complex genes 54 
has also been associated with aging, with increased expression of complexes I, III, IV and V 55 
in  12- and 18-month wild-type mice compared to 2-month mice, which was accompanied 56 
by increased oxidative damage [19]. However decreased expression of these genes was 57 
seen in older, 24-month old mice. Further evidence for a role of mitochondria in AD 58 
pathogenesis comes from a study demonstrating increased levels of mitochondrial gene 59 
expression and oxidative damage in a transgenic Amyloid Precursor Protein (APP) mutant 60 
mouse model of AD [20]. In addition, various components of the mitochondrial permeability 61 
transition pore (mPTP), which acts as a voltage-dependent channel regulating mitochondrial 62 
membrane permeability, have been shown to interact with Aβ in various murine models of 63 
AD. For example, one recent study found that, in APP transgenic mice, Aβ acts to upregulate 64 
VDAC1, a component of the mPTP, leading to mPTP blockade. [21]. Interestingly, this study 65 
also reports that VDAC1 may interact with hyperphosphorylated tau, suggesting another 66 
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mechanism of mitochondrial dysfunction. An earlier study found that Aβ present in 67 
mitochondria interacts with CypD, another component of the mPTP, in cortical samples 68 
from post-mortem AD patients and mAPP transgenic mice [22]. In the mouse model, this 69 
was shown to lead to increased ROS production and neuronal cell death. Taken together, 70 
this illustrates how mitochondrial-encoded gene expression is altered in AD, a variety of 71 
mechanisms by which Aβ interacts with mitochondria in AD, and how mitochondrial 72 
dysfunction can lead to changes associated with AD, thus highlighting the need for 73 
continued research into the field. 74 
 75 
Epigenetics and AD 76 
Given the high heritability estimates for AD [23], considerable effort has focussed on 77 
understanding the role of genetic variation in disease etiology, although more recently it has 78 
been hypothesized that epigenetic dysfunction may also be important [24]. A number of 79 
studies have shown reduced global levels of the DNA modifications 5-methylcytosine (5-mC) 80 
and 5-hydroxymethylcytosine (5-hmC) in AD brain [25-28] with only a handful of studies 81 
have looked at changes occurring at specific loci (reviewed in [24]). Recent methodological 82 
advances in microarray and genomic sequencing technologies have enabled researchers to 83 
undertake epigenome-wide association studies (EWAS) in AD brain, identifying several 84 
consistent differentially methylated regions (DMRs) associated with disease [29-31]. Many 85 
of these DMRs are tissue-specific, restricted to regions of the brain associated with AD 86 
pathology, and correlate strongly with quantitative measures of neuropathology.  As such, a 87 
strong case is being built for a role of epigenetics in the etiology of AD. 88 
 89 
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Epigenetic regulation of the mitochondrial genome 90 
Although hypotheses about the importance of mtDNA modifications are by no means 91 
recent, research in this area has been marred by contradictory results since the 1970s [32-92 
35]. The confirmation in 2011 of both 5-mC and 5-hmC occurring in mtDNA prompted a 93 
resurgence of interest in mitochondrial epigenomics [36]. The mitochondrial epigenome has 94 
some notable differences compared to the nuclear epigenome, and an overview of the 95 
mitochondrial genome, including its CpG sites, can be seen in Figure 1. Unlike the nuclear 96 
genome, the mitochondrial genome does not contain classical CpG islands [36], and is not 97 
associated with chromatin; instead it is structurally organised by nucleoids [37, 38]. As a 98 
result, mtDNA is not associated with histone proteins and relies on transcription factors 99 
such as mitochondrial transcription factor A (TFAM) to mediate compaction [39]. Histone 100 
modifications do not therefore play a direct role in regulating mitochondrial gene 101 
expression, highlighting the potential importance of DNA modifications in the regulation of 102 
mitochondrial function [40]. Evidence suggests that mtDNA methylation largely influences 103 
mtDNA structure and replication and is affected by factors which influence nucleoid 104 
compaction and DNA methyltransferase (DNMT) binding [41]. It has been shown that 105 
different areas of mtDNA are packaged differently and that a depletion of the nucleoid 106 
protein ATAD3 can reduce mtDNA methylation, resulting in an open circular state 107 
mitochondrial genome, although evidence for an effect of TFAM on mtDNA methylation was 108 
inconclusive [41]. 109 
 110 
DNMTs are a family of enzymes that catalyse the removal of a methyl group from methyl 111 
donors such as S-adenosylmethionine (SAM) for addition to the 5-position of cytosine. 112 
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Recently, a DNMT isoform, mitochondrial DNMT1 (mtDNMT1), has been found to contain a 113 
mitochondrial targeting sequence allowing it to bind to the D-loop of the mitochondrial 114 
genome, which contains the promoter sites for both the light and heavy strand of mtDNA 115 
and can therefore influence mitochondrial gene expression by altering transcriptional 116 
activity [36]. Furthermore, it has been suggested that the presence of these 117 
methyltransferases in mitochondria may be tissue-specific. Although Shock et al, did not 118 
observe mitochondrial localization of DNMT3a in the two cell lines they investigated, a later 119 
paper has found that DNMT3a is present, and in higher levels than mtDNMT1, in the 120 
mitochondria of motor neurons [42]. This study also demonstrated significantly higher 121 
global levels of both mitochondrial DNMT3a and 5-mC in Amyotrophic Lateral Sclerosis (ALS) 122 
motor neurons in vivo, suggesting a potential role for mtDNA methylation in motor neurons. 123 
DNMT1 and DNMT3b have also been observed in the mitochondria, with their inactivation 124 
reducing methylation at CpG sites [43].  125 
 126 
Recently, it has been debated whether 5-hmC is just an intermediary product of the 127 
demethylation process of 5-mC to cytosine or could represent an independent epigenetic 128 
mark [44]. Growing evidence now suggests that 5-hmC could be a mark in its own right, 129 
produced from the conversion of 5-mC by TET1, TET2 and TET3 [45], with both TET1 and 130 
TET2 being present in the mitochondria [43]. Taken together with the presence of 5-hmC in 131 
the mitochondrial D-Loop [36], this strengthens the evidence suggesting that demethylation 132 
pathways are not only important in nuclear epigenetics, but may also play a role in the 133 
mitochondria. Furthermore, recent evidence suggests that 5-mC and 5-hmC exist stably 134 
within mtDNA at cytosines not preceding a guanine base, suggesting a role for non-CpG 135 
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methylation in mtDNA [46]. Further, CpG and non-CpG methylation has been observed in 136 
the mitochondrial D-loop at conserved regions associated with DNA-RNA hybrid formation 137 
during transcription, suggesting that DNA methylation in mitochondria shares similarities 138 
with plants and fungi and that this methylation may play a role in regulating  mtDNA 139 
transcription and replication in a cell type-specific fashion [43]. 140 
 141 
MtDNA modifications in disease 142 
Despite little being known about the physiological impact of variation in mtDNA 143 
methylation, some recent studies have shown that it may be associated with a variety of 144 
diseases. The majority of studies have focussed on diseases where mitochondrial 145 
dysfunction is known to be prevalent, for example in cancer, which has been previously 146 
linked with mitochondrial dysfunction [47] and more recently in Down’s Syndrome, where 147 
mitochondrial abnormalities have also been reported [48]. Particularly, for the purpose of 148 
this review, mitochondrial dysfunction and mtDNA methylation aberrations in Down's 149 
syndrome cells (see Table 1) are interesting given that these patients have an increased 150 
likelihood of presenting with AD-like phenotypes throughout aging [49, 50] due to 151 
possessing an extra copy of  APP. An overview of studies of mtDNA epigenetics in disease is 152 
given in Table 1. 153 
 154 
MtDNA modifications: evidence for a role in AD and aging  155 
Until recently the role of mtDNA modifications in AD has been largely ignored, despite the 156 
evidence that mitochondrial dysfunction is involved in AD [18] and that ncDNA methylation 157 
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differences are associated with the disease [29-31]. At a global level, an initial dot blot study 158 
showed some evidence for increased mitochondrial 5-hmC in AD superior temporal gyrus 159 
tissue, although definitive conclusions could not be drawn given the small number of 160 
samples used [51]. Mitochondrial DNA modifications in the brain have been shown to be 161 
associated with aging, with global mtDNA 5-hmC levels reduced in the frontal cortex of aged 162 
mice and specifically decreased 5-hmC levels being found in the regulatory D-Loop, as well 163 
as in two genes encoding ETC complex I polypeptides (MT-ND2 and MT-ND5) [52]. Aging 164 
was not only found to be associated with overall decreased mtDNA 5-hmc levels but also 165 
with increased cortical expression of the mitochondrial ETC genes MT-ND2, MT-ND4, MT-166 
ND4L, MT-ND5, and MT-ND6 [52]. A post-mortem study of frontal cortex described 167 
differential mtDNA gene expression of these genes, and other mitochondrial-encoded 168 
genes, in both early and late-stage AD. [7] Taken together, these findings illustrate that 169 
alterations in mitochondrial-encoded genes do occur with aging and in age-related diseases, 170 
yet without further studies, the exact role of mtDNA methylation on mitochondrial gene 171 
expression in these instances remains uncertain. 172 
  173 
Two genomes are better than one: interactions between the nuclear and mitochondrial 174 
genomes 175 
As research into the field of mitochondrial epigenetics gains momentum, studies have 176 
focused on a potential trans-acting role of mtDNA in the epigenetic regulation of ncDNA, 177 
whereby covalent modifications across the mtDNA genome may affect not only the 178 
expression of a gene in cis, but also have trans-acting effects on the transcription of genes in 179 
the nuclear genome. Evidence for this is provided by cybrid models, which combine the 180 
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nuclear genome of one source with the mitochondrial genome of another in an attempt to 181 
determine the functional role of the mtDNA. Using Restriction Landmark Genomic Scanning 182 
(RLGS) and Rho0 cells, a form of cybrid cell line designed for investigating mtDNA depletion, 183 
one study found that mtDNA depletion significantly altered DNA methylation at CpG islands 184 
in nuclear encoded genes [53], indicating that there are functional interactions between the 185 
two genomes. Re-introduction of wild-type mtDNA restored DNA methylation levels, at 186 
some RLGS spots, suggesting that, at least for some genes, mitochondria may play a role in 187 
nuclear DNA methylation. This is corroborated by a recent study demonstrating that 188 
mitochondrial haplotype variation can affect ncDNA methylation, with mtDNA haplotype J 189 
exhibiting higher global DNA methylation levels, reduced ATP, and overexpression of the 190 
nuclear gene methionine adenosyltransferase I, alpha (MAT1A), which is required for SAM 191 
production thus regulating methylation patterns in the nuclear genome [54]. Therefore 192 
genetic variations in mtDNA are capable of influencing epigenetic modifications in both the 193 
mitochondrial and nuclear genomes. As such, it is possible that mitochondrial dysfunction in 194 
AD could lead to alterations in mtDNA methylation, affecting nuclear gene expression.  195 
 196 
The mitochondria comprises approximately 1500 proteins, however of these, only 13 are 197 
encoded by the mitochondrial genome; the remainder are encoded by the nuclear genome 198 
and imported into the mitochondria. A recent study found that >600 of these genes have 199 
tissue-specific differentially methylated regions, ultimately leading to changes in 200 
mitochondrial function dependent upon tissue type [55]. This suggests that there is an 201 
additional level of complexity to consider in the study of mitochondrial epigenetics, 202 
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whereby epigenetic changes in one genome may affect transcriptional control in another in 203 
a tissue-specific manner.  204 
 205 
Interrogating the mitochondrial epigenome: technical caveats 206 
Despite the potential importance of mitochondrial DNA modifications in AD, there are a 207 
number of technical challenges specific to interrogating the mitochondrial epigenome that 208 
have hampered widespread studies to date. These issues can be broadly summarized as 209 
encompassing genetic issues and specificity issues, which are outlined briefly with potential 210 
solutions in Table 2.  211 
1. Genetic issues 212 
1.1. Nuclear pseudogenes  213 
By far the greatest concern when analyzing mtDNA methylation arises from regions of 214 
homology between the mitochondrial genome and nuclear mitochondrial pseudogenes 215 
(NUMTs).  These genes are nuclear paralogs of mtDNA which have been translocated and 216 
inserted into the nuclear genome during evolution of both genomes [56]. This phenomena 217 
has been shown to be evolutionarily conserved across many species including cats [57], 218 
mice, chimpanzees, rhesus macaques [58] and hominins [59].  These insertions were 219 
thought to typically occur in non-coding regions; however, more evolutionary recent 220 
translocations have actually been shown to prefer integration into coding regions, thus 221 
leading to potential alterations in gene function with implications for disease [60]. NUMTs 222 
are generally small and typically comprise ~0.1% of the nuclear genome [61]. However in 223 
humans, it has been shown that some NUMTs can be as large as 14.7kb, representing a 224 
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significant portion of the ~16.6kb human mitochondrial genome [62]. As such, the presence 225 
of NUMTs can cause major issues in genomic analyses using pre-sequencing enrichment 226 
methods such as custom capture or long-range PCR as the likelihood of NUMT co-227 
amplification, or even preferential amplification, increases due to the strong sequence 228 
similarity between the two segments of genome [63]. As such, this sequence similarity can 229 
lead to the misclassification of NUMTs as mtDNA during analysis, and has led to a number of 230 
publications wrongly describing NUMTS as mtDNA [64, 65]. NUMT misclassification has also 231 
been observed in AD genetic studies whereby amplification of the NUMT sequence has led 232 
to false heteroplasmies (see below) being reported [66, 67]. One potential solution is to 233 
separate mitochondria prior to DNA extraction in an attempt to reduce the risk of 234 
contaminating the mitochondrial and nuclear genomes. However, despite extensive 235 
research being dedicated to mtDNA analysis, existing methods for mitochondrial isolation 236 
and mtDNA extraction via the use of fractional precipitation or gradient ultracentrifugation 237 
remain time consuming and labour intensive [68] and often leave residual nuclear DNA 238 
contamination following mitochondrial isolation [69].  239 
1.2.  Variation in mtDNA: haplogroups and genetic and epigenetic 240 
heteroplasmy  241 
Each mitochondrion contains between 2-10 copies of mtDNA. However, not all mtDNA in 242 
each mitochondrion share the same DNA sequence. Indeed, mutations in some copies of 243 
mtDNA mean that the cell itself may be made up of a mixture of different sequences. This 244 
phenomenon is known as mitochondrial heteroplasmy and has been linked to various 245 
mitochondrial diseases, [70]. It is a potential confounder in studies of mitochondrial 246 
diseases, because inter- and intra-individual heteroplasmic variation can confuse the 247 
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association between a haplogroup with its corresponding phenotype.  The importance of 248 
this issue, in the context of this review, is highlighted by a recent study demonstrating that 249 
mitochondrial heteroplasmy alters DNA methylation across the nuclear-encoded 250 
mitochondrial genes TFAM and POLMRT [71]. Finally, if mtDNA methylation is altered across 251 
different mtDNA in the same mitochondrion, it could create an epigenetic mosaic within the 252 
mitochondrion, the cell and across the tissue, whereby each copy of mtDNA may possess its 253 
own methylation profile. If this ‘methylomic heteroplasmy’ were to occur it could be very 254 
difficult to tease apart the effects of such a mosaic in functional studies. 255 
 256 
On a larger scale, mutations in mtDNA can be used to help group cohorts or "haplogroups". 257 
Throughout evolution, mutations in mtDNA may be conserved and passed on through 258 
maternal inheritance, thus allowing for the tracing of common ancestral lineage by 259 
comparing haplogroups. Numerous studies have identified both contributory and protective 260 
effects of different haplogroups in AD. For example, haplogroup K reduces the risk of 261 
developing sporadic AD in Apolipoprotein ε4 (APOε4) carriers in an Italian population [72] 262 
but not in the Polish population [73]. This presents an additional potential caveat in 263 
mitochondrial epigenetics, as mitochondrial haplogroups have been found to affect global 264 
levels of DNA methylation [54]. As such, extra care should be taken to account for 265 
haplogroup variability in AD mitochondrial epigenetic studies.   266 
2. Specificity and technical issues 267 
The brain is a complex, heterogeneous organ with numerous functionally-distinct sub-268 
regions, each with their own different composition of cell types. Unsurprisingly, there are 269 
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clear tissue-specific epigenetic differences across brain regions [74, 75]. There is an added 270 
level of complexity with respect to the mitochondrial epigenome because each 271 
mitochondrion contain between 2-10 copies of mtDNA and each cell contains varying levels 272 
of mitochondria; therefore the amount of mtDNA copies in each cell can vary between 100-273 
10,000 dependent upon cell type. In neurodegenerative diseases such as AD, the issue 274 
becomes more complicated in that the disease itself is characterized by the loss of neuronal 275 
cells and the activation of glia, a process that has been associated with changes in 276 
mitochondrial morphology and fission [76, 77]. A recent study using laser capture 277 
microdissection demonstrated that alterations in mitochondrial 5-hmC are seen with age in 278 
dissected mouse cerebellar purkinje cells, which was not evident in whole cerebellar tissue 279 
[52], demonstrating the importance of cell-specific analyses in heterogeneous tissue, 280 
particularly when investigating functional impact. 281 
 282 
Currently, the most common method of measuring DNA methylation is via the conversion of 283 
DNA with sodium bisulfite followed by subsequent sequence analysis. However, these 284 
approaches are unable to distinguish between 5-mC and 5-hmC [78], an important 285 
limitation given recent studies confirmed the presence of 5-hmC in mitochondria in brain 286 
tissue [52]. Studies have found that although both DNA modifications are present in the 287 
mitochondria, they occur at much lower levels compared to in ncDNA [36, 51], and thus 288 
methods used for quantification may need to be more sensitive. Furthermore, variation in 289 
mitochondrial copy number may lead to the dilution of signals and reduce detection if the 290 
tissue is largely heterogeneous. Importantly, the mitochondrial genome is not interrogated 291 
using tools such as the Illumina Infinium 450K methylation array, the current gold standard 292 
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for methylomic analyses in large numbers of samples; thus methods for detecting mtDNA 293 
modifications across the entire mitochondrial genome are largely restricted to antibody-294 
based enrichment, such as MeDIP-Seq, which may be less sensitive for detecting low levels 295 
of modified cytosine and does not interrogate methylation levels at single base resolution 296 
[79]. 297 
 298 
Future Perspective: the potential for biomarkers in AD 299 
Two important goals of research into the etiology of AD are a) a fast, non-invasive, 300 
inexpensive and reliable biomarker and b) an effective treatment that targets the underlying 301 
neuropathology. A potential utility for DNA methylation biomarkers has been proposed for 302 
diseases in which traditional biomarkers are either too expensive, invasive, unspecific or  303 
insensitive for clinical purposes [80]. Epigenetic modifications have been widely studied in a 304 
variety of different cancers and other conditions such as preeclampsia to check for their 305 
suitability as prognostic and/or diagnostic biomarkers [81-83]. Differential methylation of 306 
mtDNA has yet to be examined with respect to its potential utility as an AD biomarker, but 307 
certainly warrants further investigation. 308 
 309 
Conclusion 310 
With mitochondrial epigenetics only recently emerging as a focus for biomedical research, 311 
the role of the mitochondrial epigenome in AD has yet to receive much attention. However, 312 
it is possible that deregulation of the mitochondrial methylome may lead to aberrant 313 
changes in many of the intricately controlled processes that it helps to govern, such as 314 
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apoptosis, which may play a key role in pathogenesis. Furthermore, as mitochondrial 315 
dysfunction occurs early in AD pathogenesis, it is plausible that alterations in the 316 
mitochondrial methylome may play a major role in the onset and development of the 317 
disease. Despite the field presenting numerous challenges the links between mitochondrial 318 
epigenetics and AD provide good bounds for future research directions. 319 
 320 
EXECUTIVE SUMMARY 321 
Mitochondrial dysfunction: a prominent feature of AD 322 
 The mitochondrial genome plays a vital role in a variety of key biological functions, 323 
including apoptosis via caspase dependant and independent mechanisms, regulating 324 
calcium homeostasis and production of ROS. 325 
 Mitochondrial dysfunction is reported to occur in both the brain and blood of AD 326 
patients. 327 
EWAS and AD 328 
 Studies focussing on global levels of 5-mC and 5-hmC have found a reduction in 329 
levels of both marks in AD brain.  330 
 Three recent EWAS studies have found differential methylation at specific loci in AD 331 
brain. 332 
Epigenetic regulation of the mitochondria genome 333 
 Despite early controversial results, both 5-mC and 5-hmC have been recently 334 
reported in mitochondria.  335 
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 MtDNA is not tightly wrapped by histones and is instead condensed by nucleoids, 336 
suggesting methylation could play an important role in gene regulation. 337 
 DNMT1 can bind to the D-Loop of the mitochondrial genome and can influence gene 338 
expression. 339 
 MtDNA methylation occurs at both CpG sites and non-CpG site in the mitochondrial 340 
genome. 341 
MtDNA methylation: a key player in AD? 342 
 Very few empirical studies have examined the role of mtDNA methylation in brain.  343 
 Decreased mtDNA 5-hmC levels and increased expression of some mitochondrial-344 
encoded genes has been seen in the pre-frontal cortex of aged mice. 345 
Technical caveats 346 
 NUMT misclassification has been observed in AD genetic studies whereby 347 
amplification of the NUMT sequence has led to false heteroplasmies being reported. 348 
 MtDNA methylation could be altered in different mitochondria, creating a 349 
methylomic heteroplasmy. 350 
 MtDNA methylation patterns could be cell-specific and is an important consideration 351 
when investigating heterogeneous tissues such as brain.  352 
 353 
 354 
 355 
 356 
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 357 
Figure 1: The structure of the mitochondrial genome showing genes encoded by the 358 
mitochondria. 3358 mtDNA genetic variants are shown in red and black lines highlight the 359 
predicted CpG sites relative to mutations that define the mitochondrial haplogroup. PH and 360 
PL represent the heavy and light strand promoter regions and OH and OL represent the 361 
origins of heavy-strand and light-strand replication respectively.  Image taken from [84]. 362 
 363 
 364 
 365 
 366 
 367 
 368 
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Table 1: An overview of current studies of mitochondrial epigenetics in disease. 369 
Abbreviations: Quantitative Real-Time PCR (qRT-PCR), mitochondrial DNA (mtDNA), simple 370 
steatosis (SS), non-alcoholic steatohepatitis (NASH), S-adenosylmethionine (SAM) , Liquid 371 
chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS), Liquid 372 
chromatography mass spectrometry (LC-MS), Immunofluorescence (IF), Amyotrophic lateral 373 
sclerosis (ALS). 374 
 375 
 376 
Research Question Techniques Main Findings Reference 
The effect of different environmental 
exposures (metal-rich particulate 
matter, air benzene levels and traffic 
derived elemental carbon levels) on 
mitochondria 
Pyrosequencing  
qRT-PCR  
Increased exposure to particulate matter increases MT-
RNR1 and MT-TF gene methylation 
 
Increased MT-RNR1 methylation is associated with a 
significant increase in mtDNA copy number. 
[85] 
The effect of mtDNA methylation in 
the mitochondrial D-Loop on gene 
expression in colorectal cancer cells. 
Methylation-
specific PCR  
 
Western blotting  
An increased level of demethylated sites in the D-Loop of 
tumour cells is strongly associated with increased MT-
ND2 expression and mtDNA copy number. 
[47] 
The effect of methylation in the D-
Loop, MT-ND6 and MT-CO1 on 
disease progression in simple 
steatosis (SS) and non-alcoholic 
steatohepatitis (NASH) 
Methylation-
specific PCR  
 
qRT-PCR  
Increased MT-ND6 methylation and decreased MT-ND6 
protein levels in NASH compared to SS. Physical activity 
reduced MT-ND6 methylation in NASH. 
 
[86] 
The effect of decreased S-
adenosylmethionine (SAM) on 
mtDNA methylation in Down’s 
Syndrome lymphoblastoid cells 
LC-ESI-MS 
 
LC-MS/MS 
Decreased SAM availability in Down's syndrome 
lymphoblastoid cells reduces methyl uptake to 
mitochondria and leads to mtDNA hypomethylation. 
[87] 
The tissue specificity of DNMTs and 
5-mC in the mitochondria in relation 
to ALS models. 
IF  
 
Pyrosequencing  
Increased methylation at six cytosine sites in the 16S 
rRNA gene in the spinal cord of an ALS mouse cell line.  
 
Reduced levels of mtDNMT3a protein in skeletal muscle 
and spinal cord early in disease. 
 
 
  
[88] 
The effect of mtDNA methylation on 
mtDNA copy number in gastric 
cancer. 
qRT-PCR 
 
Pyrosequencing 
 
Reduced mtDNA copy number levels in late 
clinicopathological stages. 
 
Demethylation of mtDNA increases mtDNA copy number. 
 [89] 
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Table 2: A summary of the major issues and potential solutions in the field of mitochondrial epigenetics. Abbreviations: nuclear 
mitochondrial pseudogenes (NUMTs), fluorescence-activated cell sorting (FACS), laser capture microdissection (LCM). 
Caveat Potential Issues Potential Solutions 
Genetic Issues 
 
Wrongful Incorrect determination of 
pseudogenes as mtDNA affects the validity of 
results. 
1.   Isolate mitochondria before mtDNA extraction to avoid nuclear contamination 
2.  Specific primers designed with the consideration of NUMT amplification [90]. 
3.  BLAST search to identify known NUMTs 
Genetic mutations in mtDNA may have specific 
associated methylation signatures. 
Haplogroup and heteroplasmy studies should consider mtDNA methylation as a potential 
variable 
Cell Specificity and 
Technical Issues 
Different brain regions have differential 
methylation patterns and different cell 
population compositions. 
1. Larger samples sizes in specific brain subregions will improve statistical significance 
2. FACS or LCM to separate cell types such as glia and neurons prior to analysis. 
Reduced methylation levels in mitochondria 
and variation in mtDNA copy number may 
increase noise and dilute signals. 
Comparative analysis of techniques for their suitability to mitochondrial methylation studies 
should be considered. 
Bisulfite based methodologies cannot 
distinguish between 5-mC and 5-hmC. 
Using oxidative bisulfite-sequencing allows for the distinction of 5-mC and 5-hmC at single base 
resolution[91]. 
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REFERENCE ANNOTATIONS 
 Bellizzi et al., 2013 –reported both 5-mC and 5-hmC in mtDNA at both CpG and non-
CpG sites. The study also found that inactivation of DNMT1, DNMT3a and DNMT3b 
reduced CpG methylation levels markedly, but failed to impact non-CpG methylation 
to the same extent. As such, this study poses the question as to whether DNMT 
activity is important for mitochondrial methylation, or whether other factors may 
also be important. 
 Chestnut et al., 2011 – found that DNMT3a was localized in the mitochondria of 
motor neurons, potentially indicating tissue-specific localization of this 
methyltransferase. This study also found 5-mC in mitochondria in vivo, suggesting 
that mitochondrial methylation may play a role in motor neurons. 
 Dzitoyeva et al., 2012- found that the global levels of 5-hmC in mtDNA show an age-
associated decrease in murine frontal cortex and that this was inversely correlated 
with the expression of some mitochondrial genes, suggesting a potential role of 
mtDNA methylation in aging.  
 Lunnon et al., 2014 – used Illumina Infinium 450K methylation beadarray to 
demonstrate DNA methylation changes in AD cortex. 
 Manczak et al., 2004 –investigated expression levels of mitochondrial-encoded ETC 
genes in AD, reporting decreased expression of complex I and increased expression 
of complex III and IV in early and late-stage disease. 
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 Shock et al., 2011 – reported 5-mC and 5-hmC in mtDNA, leading to a resurgence of 
interest in the field of mitochondrial epigenetics. This paper also identified an 
isoform of DNMT1, mtDNMT1, in the mitochondria. 
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